Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 407-000-3 | CAS number: 127519-17-9 CGL 384; TINUVIN 384
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Developmental toxicity / teratogenicity
Administrative data
- Endpoint:
- developmental toxicity
- Type of information:
- migrated information: read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Study period:
- 2013
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: GLP and OECD guideline compliant study with well characterized test material. A reduction in reliability is assigned for use as read-across.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 013
- Report date:
- 2013
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 414 (Prenatal Developmental Toxicity Study)
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Limit test:
- no
Test material
- Reference substance name:
- A mixture of: α-3-(3-(2H-benzotriazol-2-yl)-5-tert-butyl-4-hydroxyphenyl)propionyl-ω-hydroxypoly(oxyethylene); α-3-(3-(2H-benzotriazol-2-yl)-5-tert-butyl-4-hydroxyphenyl)propionyl-ω-3-(3-(2H-benzotriazol-2-yl)-5-tert-butyl-4-hydroxyphenyl)propionyloxypoly(oxyethylene)
- EC Number:
- 400-830-7
- EC Name:
- A mixture of: α-3-(3-(2H-benzotriazol-2-yl)-5-tert-butyl-4-hydroxyphenyl)propionyl-ω-hydroxypoly(oxyethylene); α-3-(3-(2H-benzotriazol-2-yl)-5-tert-butyl-4-hydroxyphenyl)propionyl-ω-3-(3-(2H-benzotriazol-2-yl)-5-tert-butyl-4-hydroxyphenyl)propionyloxypoly(oxyethylene)
- Molecular formula:
- The substance is a mixture of a number of chemical entities, of which there are two principal components : (C2H4O)6-7C19H21N3O3 (major product) (C2H4O)6-7C38H40N6O5 (minor product)
- IUPAC Name:
- 400-830-7
- Test material form:
- liquid: viscous
- Details on test material:
- - Physical state: liquid (clear yellow)
- Analytical purity: 100 % (UVCB substance)
- Expiration date of the lot/batch: 15. October 2015
- Stability under test conditions: stable
- Storage condition of test material: sealed container, 15 -25°C, in the dark
- Other: alternative identifiyer: EC 400-830-7
- Structural formula attached as image file (if other than submission substance): see Fig. for the teratogenicity study in rats.
Constituent 1
Test animals
- Species:
- rabbit
- Strain:
- New Zealand White
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Covance Research Products, Pennsylvania, USA.
- Age at study initiation: no data
- Weight at study initiation: At mating the female rabbits weighed at least 2.5 kg
- Fasting period before study: none
- Housing: single cages
- Diet (e.g. ad libitum): ad libitum
- Water (e.g. ad libitum): ad libitum
- Acclimation period: three days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 15 to 21°C
- Humidity (%): at least 45%
- Air changes (per hr): 15 to 20
- Photoperiod (hrs dark / hrs light): 12/12
IN-LIFE DATES: From: 30. April 2013 To: 23 May 2013
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- other: 0.5% aqueous carboxymethylcellulose
- Details on exposure:
- PREPARATION OF DOSING SOLUTIONS: Formulations of the test article in the vehicle were prepared daily.
VEHICLE
- Justification for use and choice of vehicle (if other than water): Substance is not soluble in water, but dispersible in the vehicle.
- Concentration in vehicle: adjusted to dose
- Amount of vehicle (if gavage): 10 mL/kg.
All animals were given a small amount of irradiated meadow hay (IPS, Finedon, Northants) at intervals throughout the study. This was offered as environmental enrichment only and was not included in any food consumption calculations.
On several occasions during the study it was necessary to provide some animals with hay moistened with water due to inappetance. This was not included in any food consumption calculations. - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Samples from formulations prepared for use on the first day of dosing were taken for analysis of achieved concentration. In addition three samples were taken from formulations on the last day of dosing. The mean of the homogeneity results was taken as the achieved concentration where the sampling occasion coincided.
Samples were analysed by the Formulations Analysis section of the contract research facility. - Details on mating procedure:
- - Impregnation procedure: purchased timed pregnant (The females were delivered on Day 3 of gestation.)
- Duration of treatment / exposure:
- Day 6 to Day 28 of gestation, inclusive
- Frequency of treatment:
- daily
- Duration of test:
- Animals were sacrificed on gestaton day 29.
Doses / concentrations
- Remarks:
- Doses / Concentrations:
10, 30 and 100 mg/kg bw
Basis:
actual ingested
- No. of animals per sex per dose:
- 24
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- Based on the dose-range-finding study in five pregnant rabbits per group, 10 mg/kg bw was expected to show no maternal toxicity. The dose level of 300 mg/kg bw dosed to pregnant rabbits in study 8280620 resulted in body weight loss and animals had to be sacrificed. A dose levels of 150 mg/kg/day elicited reduced food intake and reduced body weight gain. A dose level of 50 mg/kg/day elicited slightly increased liver weight only, and so a dose level of 100 mg/kg/day was deemed to be a suitable high dose level for this study.
Examinations
- Maternal examinations:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: beginning and end (nominal) of the working day.
- Post dosing observation: Daily: upon return to the home cage and at 0.5, 1, 2 and 4 hours post dose.
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: Days 0 (at supplier), 3, 6, 7, 8, 9, 12, 15, 17, 19, 22, 25, 28 and 29 of gestation.
BODY WEIGHT: Yes
- Time schedule for examinations: Days 0 (at supplier), 3, 6, 7, 8, 9, 12, 15, 17, 19, 22, 25, 28 and 29 of gestation.
FOOD CONSUMPTION : Yes
- Food consumption for each animal determined (grams) and calculated as g/animal/day.
POST-MORTEM EXAMINATIONS: Yes
- Sacrifice on gestation day 29
OTHER: - Ovaries and uterine content:
- The ovaries and uterine content was examined after termination: Yes
Examinations included:
- Gravid uterus weight: Yes
- Number of corpora lutea: Yes
- Number of implantations: Yes
- Number of early resorptions: Yes
- Number of late resorptions: Yes
- Other: intrauterine position of implantation sites
- numer of live/dead foetuses - Fetal examinations:
- External examinations: Yes: all per litter
- Soft tissue examinations: Yes: all per litter
- Skeletal examinations: Yes: all per litter
- Head examinations: Yes: half per litter
external foetal assessment
foetal weight
placental weight
foetal sex- Statistics:
- All variables were analysed with a twosided risk except where stated below. Body weight gains, Day 29 corrected body weights, food intake and litter weights were analysed using one-way analysis of variance (ANOVA). Levene's test for equality of variances among the groups was performed. Where this showed no evidence of heterogeneity (P0.01), pairwise comparisons with control were made using Dunnett's test. A linear contrast was performed to determine whether there was a relationship between increasing dose and response. A significant trend (P<0.05) was only reported where none of the pairwise comparisons was significant. Where Levene’s test showed evidence of heterogeneity (P<0.01), as the data were unsuitable for log-transformation, non-parametric methods were used. Placental weights, the percentage of male foetuses and the numbers of corpora lutea, implantations and foetuses per female were analysed using non-parametric methods. The non-parametric methods employed were the Kruskal-Wallis ANOVA, the Terpstra-Jonckheere test for a dose related trend and the Wilcoxon rank sum test for pairwise comparisons. Where the Kruskal-Wallis ANOVA was not significant, the pairwise comparisons were not reported in order to protect the Type I error. Foetal weights were analysed using Analysis of Covariance (ANCOVA) and Dunnett's test, using the litter size as covariate. This analysis depends on the assumption that the relationship between the foetal weight and the covariate is the same for all groups, and the validity of this assumption was tested. Levene's test for equality of variances across the groups was also performed and this showed no evidence of heterogeneity (P<=0.01). Gravid uterus weights were analysed using Analysis of Covariance (ANCOVA) and Dunnett's test, using the corrected body weight on day 29 as covariate. This analysis depends on the assumption that the relationship between the organ weight. Further information available, but maximum size limit reached.
- Indices:
- Percentage pre-implantation loss
Percentage post-implantation loss
Percentage male foetuses - Historical control data:
- included in report for 6 studies performed by supplier
Results and discussion
Results: maternal animals
Maternal developmental toxicity
- Details on maternal toxic effects:
- Maternal toxic effects:yes
Details on maternal toxic effects:
Food consumption was dose-dependently reduced at 100 and 30 mg/kg bw/day (Table 1, data for females excluding those with aborations). Body weight gains between gestation day 6 and 29 were decreased by approximately 20% at 30 mg/kg bw/day, and by approximately 70% at 100 mg/kg bw/day (Figure 1 and Table 3).
In animals receiving 100 mg/kg/day eight animals were killed after aborting their pregnancies between Days 20 to 28 of gestation (Table 2). Many of these animals had few faeces, poor food consumption and body weight loss, so their demise was considered to be treatment-related. The abortion is considered to be a consequence of the maternal toxicity as indicated by the very poor food consumption.
There were no post-dosing observations and no further clinical signs.
Other than the thin animals, there were no treatment-related findings at necropsy (Table 7).
Individual data on food consumption and body weights are given in the attachment.
Effect levels (maternal animals)
- Dose descriptor:
- NOEL
- Effect level:
- 10 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Basis for effect level:
- other: maternal toxicity
Results (fetuses)
- Details on embryotoxic / teratogenic effects:
- Embryotoxic / teratogenic effects:no effects
Details on embryotoxic / teratogenic effects:
Mean foetal weight and therefore mean litter weight were reduced compared with controls at 100 mg/kg/day (17% and 25%, respectively, table 5) and this was considered to be as a result of the marked maternal toxicity seen at that dose level. Other foetal parameters were unaffected by treatment (see table 6 and attachment).
Effect levels (fetuses)
- Dose descriptor:
- NOEL
- Effect level:
- >= 100 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Basis for effect level:
- other: teratogenicity
Fetal abnormalities
- Abnormalities:
- not specified
Overall developmental toxicity
- Developmental effects observed:
- not specified
Any other information on results incl. tables
Table 1: Mean food intake of dams (excluding females with abortions)
Mean food intake (g/animal/day) |
|||||
Days of gestation | control | 10 mg/kg bw | 30 mg/kg bw | 100 mg/kg bw | Statistics |
3-5 | 157 | 153 | 157 | 160 | X |
6 | 159 | 162 | 133 | 112** | A |
7 | 150 | 146 | 129 | 82*** | A |
8 | 146 | 144 | 112** | 64*** | A |
9-11 | 141 | 131 | 108* | 61*** | A |
12-14 | 123 | 100 | 81* | 51*** | A |
15-16 | 130 | 100 | 87* | 58*** | A |
17-18 | 152 | 133 | 105** | 87*** | A |
19-21 | 132 | 117 | 103 | 98* | A |
22-24 | 108 | 108 | 101 | 80* | A |
25-27 | 96 | 96 | 94 | 48*** | A |
28 | 96 | 93 | 95 | 55*** | A |
A = ANOVA, dose response and Dunnett's | * P<0.05 | ||||
X = not analysed | ** P<0.01 | ||||
*** P<0.001 |
Table 2 Summary of female performance
control | 10 mg/kg bw | 30 mg/kg bw | 100 mg/kg bw | |
In group | 24 | 24 | 24 | 24 |
Not pregnant | 1 | 3 | 1 | 0 |
Pregnant (%) | 23 (95.8) | 21 (87.5) | 23 (95.8) | 24 (100.0) |
Aborted and killed | 0 | 0 | 0 | 8 |
Died/killed* | 2 | 0 | 2 | 1 |
With total embryo/foetal loss | 0 | 0 | 0 | 0 |
With live foetuses on Day 29 | 21 | 21 | 21 | 15 |
*Death was due to dosing errors and not related to treatement.
Table 3: Group mean body weights (kg) excluding females with abortions | ||||
day of gestation | control | 10 mg/kg bw | 30 mg/kg bw | 100 mg/kg bw |
3 | 3.24 | 3.20 | 3.22 | 3.22 |
6 | 3.35 | 3.34 | 3.35 | 3.34 |
7 | 3.35 | 3.33 | 3.33 | 3.31 |
8 | 3.36 | 3.33 | 3.31 | 3.26 |
9 | 3.36 | 3.34 | 3.30 | 3.25 |
12 | 3.41 | 3.36 | 3.32 | 3.24 |
15 | 3.47 | 3.42 | 3.37 | 3.30 |
17 | 3.50 | 3.44 | 3.38 | 3.34 |
19 | 3.53 | 3.48 | 3.41 | 3.37 |
22 | 3.60 | 3.54 | 3.47 | 3.40 |
25 | 3.64 | 3.59 | 3.53 | 3.45 |
28 | 3.67 | 3.63 | 3.57 | 3.44 |
29 | 3.69 | 3.67 | 3.63 | 3.45 |
% body weight change; days | ||||
3-6 | 3.3 | 4.3 | 3.9 | 3.7 |
6-28 | 9.7 | 9.0 | 6.9 | 2.9 |
28-29 | 0.6 | 1.1 | 1.5 | 0.5 |
Table 4: Group mean caesarian data – uterine/implantation data
control | 10 mg/kg bw | 30 mg/kg bw | 100 mg/kg bw | statistics | |
Number of females with live foetuses on Day 29 gestation | 21 | 21 | 21 | 15 | |
Mean number of corpora lutea per female | 10.5 | 10.7 | 10.2 | 10.7 | J |
Mean number of implantations per female | 8.9 | 10.2 | 9.1 | 8.7 | J |
Pre-implantation loss: mean% |
14.0 | 4.6 | 10.6 | 17.6 | |
number of dams affected | 15 | 6 | 10 | 9 | F+ |
Early intrauterine deaths: mean number |
0.2 | 0.2 | 0.2 | 0.3 | |
number of dams affected | 4 | 3 | 3 | 4 | F+ |
Late intrauterine deaths: | |||||
mean number | 0.1 | 0.3 | 0.3 | 0.3 | |
number of dams affected | 2 | 4 | 4 | 3 | F+ |
Dead foetuses: | |||||
mean number | 0.0 | 0.0 | 0.0 | 0.1 | |
number of dams affected | 0 | 0 | 0 | 1 | F+ |
Post-implantation loss | |||||
mean% | 2.9 | 4.4 | 4.8 | 8.1 | |
number of dams affected | 5 | 7 | 5 | 7 | F+ |
Mean number of foetuses per female | 8.6 | 9.8 | 8.6 | 8.0 | J |
F+ = Cochran-Armitage and Fisher's Exact (upper tail) | |||||
J = Kruskal-Wallis, Terpstra-Jonckheere, Wilcoxon |
Table 5: Group mean caesarian data - foetal data
control | 10 mg/kg bw | 30 mg/kg bw | 100 mg/kg bw | statistics | |
Number of male foetuses | 99 | 103 | 91 | 65 | |
Number of female foetuses | 82 | 102 | 90 | 55 | |
Mean % male foetuses | 55.6 | 49.8 | 51.4 | 57.1 | J |
Mean litter weight (g) | 338.8 | 357.0 | 315.5 | 255.2*** | A |
Mean placental weight (g) | 4.92 | 4.83 | 4.69 | 4.91 | J |
Mean foetal weight (g) Adjusted | 39.4 | 38.1 | 37.0 | 31.7*** | C |
Mean foetal weight (g) Unadjusted | (39.6) | (36.9) | (37.3) | (32.7) | |
Mean foetal weight (g) - males only, Adjusted | 40 | 37.9 | 37.7 | 31.9*** | C |
Mean foetal weight (g) - males only, Undjusted | (40.3) | (36.8) | (38.0) | (32.9) | |
Mean foetal weight (g) - females only, Adjusted | 38.7 | 38.0 | 36.1 | 30.4*** | C |
Mean foetal weight (g) - females only, Unadjusted | (39) | (37.0) | (36.4) | (31.0) |
J = Kruskal-Wallis, Terpstra-Jonckheere, Wilcoxon
A = ANOVA, dose response and Dunnett's
C = ANCOVA and Dunnett’s
* P<0.05, ** P<0.01, *** P<0.001
Table 6: Group mean foetal defect data
control | 10 mg/kg bw | 30 mg/kg bw | 100 mg/kg bw | statistics | |
EXTERNAL/VISCERAL DEFECTS | |||||
Number of foetuses examined | 181 | 205 | 181 | 120 | |
Number of litters examined | 21 | 21 | 21 | 15 | |
Number showing malformations | 2 | 4 | 3 | 3 | |
Mean % of foetuses examined | 1.1 | 2.0 | 1.5 | 2.0 | |
Number of litters affected | 2 | 2 | 3 | 2 | F+ |
Number showing variations | 82 | 125 | 115 | 85 | |
Mean % of foetuses examined | 46.9 | 61.5 | 64.6 | 69.5 | |
Number of litters affected | 20 | 21 | 21 | 15 | F+ |
SKELETAL DEFECTS | |||||
Number of foetuses examined | 181 | 205 | 181 | 120 | |
Number of litters examined | 21 | 21 | 21 | 15 | |
Number showing malformations | 1 | 3 | 3 | 2 | |
Mean % of foetuses examined | 0.6 | 1.4 | 1.6 | 1.5 | |
Number of litters affected | 1 | 3 | 3 | 2 | F+ |
Number showing variations | 147 | 163 | 146 | 105 | |
Mean % of foetuses examined | 80.8 | 78.2 | 81.4 | 87.6 | |
Number of litters affected | 21 | 21 | 21 | 15 | F+ |
Total number of foetuses showing malformations | 3 | 7 | 5 | 4 | |
% of foetuses examined | 1.7 | 3.4 | 2.8 | 3.3 | |
Number of litters affected | 3 | 5 | 5 | 3 | F+ |
F+ = Cochran-Armitage and Fisher's Exact (upper tail)
Table 7: Summary of necropsy findings
control | 10 mg/kg bw | 30 mg/kg bw | 100 mg/kg bw | |
Number of animals examined (females with live fetuses on day 29) | 21 | 21 | 21 | 15 |
Number of animals with finding: | ||||
Not remarkable (%) | 17 (81.0) | 15 (71.4) | 18 (85.7) | 12 (80.0) |
Animal - Thin | 1 | 2 | 3 | |
Ear - Lesion | 1 | 1 | ||
Heart - Abnormal contents | 1 | |||
Heart - Abnormal fluid | 1 | 1 | ||
Heart - Raised area | 1 | |||
Liver - Mottled | 2 | 2 | ||
Liver - Pale | 2 | 1 | ||
Lung - Adhesion | 1 | |||
Lung - Dark | 2 | |||
Lung - Dark focus | 1 | 1 | 1 | |
Lung - Raised area | 1 | |||
Ovary - Dark focus | 1 | |||
Thoracic cavity - Clear fluid | 1 | |||
Thoracic cavity - Mass multiple | 1 | |||
Thymus - Dark | 1 |
The formulations were to be considered homogeneous if the coefficient of variation (CV) of the results was equal or less than 6.0% and the homogeneity results were within ± 10% of the mean. The results were within these criteria.The target range for the preparation of the formulations was 90 to 110% of nominal. Results were within this range. Test article was not detected in the Group 1 control samples.
Applicant's summary and conclusion
- Conclusions:
- The substance is not teratogenic or embryotoxic in rabbits.
- Executive summary:
Administration to pregnant rabbits at a dose level of 100 mg/kg/day elicited toxicity in the form of reduced food intake, reduced body weight gain, eight aborted pregnancies, and reduced foetal weight.
The dose level of 30 mg/kg/day elicited effects of a slight reduction in food intake and body weight gain. The maternal No-Observed-Adverse-Effect-Level (NOAEL) was 10 mg/kg/day. The No-Observed-Effect-Level (NOEL) for embryo-foetal development was 100 mg/kg/day.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.